Medicenna Therapeutics Corp is seeing a notable decline, with shares down 3.85% in the last trading session.
Medicenna Therapeutics Corp (MDNA.TO) is having a tough day on the TSX as its stock price has dropped significantly, closing at CA$0.38. This decline raises questions about the company's current market position and future prospects.
Investor takeaway: Investors should be cautious as Medicenna's recent performance suggests potential volatility and uncertainty in the biotech sector.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$33.23M
52W high
$1.97
52W low
$0.34
1W change
+2.86%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 788.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+788.9% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
34.7%
Annualized
90-Day Vol
67.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.30
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.38 |
| 60 trading days | C$0.32 | C$0.27 – C$0.38 |
| 90 trading days | C$0.30 | C$0.24 – C$0.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Despite today's decline, Medicenna has some promising clinical developments. The recent dosing of patients in the NEO-CYT study could lead to positive news in the future.
Bear case
The stock's drop may reflect investor concerns about the company's ability to maintain growth and secure funding, especially after its recent public offerings.
Recent Performance Overview
In the latest trading session, Medicenna's stock fell by 3.85%, closing at CA$0.38. This decline is significant for a company with a market cap of CA$34.61 million, indicating investor apprehension regarding its financial health and growth prospects.
Advertisement
Market Reactions and Investor Sentiment
The drop in Medicenna's stock might be due to investor worries over the company's funding strategies, particularly following its recent public offerings. The market's reaction shows that investors are cautious about the potential risks in the biotech sector, especially for companies still in the clinical trial phase.
Looking Ahead: What’s Next for Medicenna?
Despite the current downturn, Medicenna's ongoing clinical trials, like the NEO-CYT study, could provide future growth opportunities. Investors should keep an eye on upcoming announcements and clinical results, as these could significantly impact the stock's performance.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
